Julia Koerner
Overview
Explore the profile of Julia Koerner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tondeur E, Voerman J, Geleijnse M, van Hofwegen L, van Krimpen A, Koerner J, et al.
J Immunol
. 2023 Aug;
211(8):1203-1215.
PMID: 37638825
The induction of CTL responses by vaccines is important to combat infectious diseases and cancer. Biodegradable poly(lactic-co-glycolic acid) (PLGA) microspheres and synthetic long peptides are efficiently internalized by professional APCs...
2.
Ahmed A, Reinhold C, Breunig E, Phan T, Dietrich L, Kostadinova F, et al.
Mol Oncol
. 2023 Mar;
17(8):1545-1566.
PMID: 36861295
Control of tumour development and growth by the immune system critically defines patient fate and survival. What regulates the escape of colorectal tumours from destruction by the immune system remains...
3.
Koerner J, Horvath D, Oliveri F, Li J, Basler M
Oncoimmunology
. 2022 Dec;
12(1):2156091.
PMID: 36531689
New treatment options to battle hormone-refractory prostate carcinoma (PC) are a pressing medical need. Chronic inflammation has been implicated in PC etiology. The pro-inflammatory cytokines IL-6, IL-23 and IL-17 are...
4.
Koerner J, Horvath D, Herrmann V, MacKerracher A, Gander B, Yagita H, et al.
Nat Commun
. 2021 May;
12(1):2935.
PMID: 34006895
With emerging supremacy, cancer immunotherapy has evolved as a promising therapeutic modality compared to conventional antitumor therapies. Cancer immunotherapy composed of biodegradable poly(lactic-co-glycolic acid) (PLGA) particles containing antigens and toll-like...
5.
Koerner J, Horvath D, Groettrup M
Front Immunol
. 2019 Apr;
10:707.
PMID: 31024545
With emerging success in fighting off cancer, chronic infections, and autoimmune diseases, immunotherapy has become a promising therapeutic approach compared to conventional therapies such as surgery, chemotherapy, radiation therapy, or...
6.
Li J, Koerner J, Basler M, Brunner T, Kirk C, Groettrup M
Kidney Int
. 2019 Jan;
95(3):611-623.
PMID: 30685098
Chronic antibody-mediated rejection is the leading cause of allograft dysfunction and loss after kidney transplantation, and current immunosuppressive regimens fail to target the plasma cells that produce alloantibodies. We previously...
7.
Basler M, Maurits E, de Bruin G, Koerner J, Overkleeft H, Groettrup M
Br J Pharmacol
. 2017 Oct;
175(1):38-52.
PMID: 29034459
Background And Purpose: Multicatalytic endopeptidase complex-like-1 (β2i), low molecular mass polypeptide (LMP) 2 (β1i) and LMP7 (β5i) are the proteolytically active subunits of the immunoproteasome, a special type of proteasome...
8.
Koerner J, Brunner T, Groettrup M
Oncotarget
. 2017 Sep;
8(31):50873-50888.
PMID: 28881611
New treatment options and drug targets for colorectal carcinoma are a pressing medical need. Inflammation and pro-inflammatory cytokines produced by Th1 and Th17 cells like IL-6, TNF, IL-17 and IL-23...
9.
Sommershof A, Scheuermann L, Koerner J, Groettrup M
Brain Behav Immun
. 2017 May;
65:140-149.
PMID: 28457810
Animal tumor models and human cancer studies have provided convergent evidence that chronic psychological stress plays a decisive role in modulating anti-tumor T cell immunity. However, whether chronic stress also...
10.
Mueller M, Reichardt W, Koerner J, Groettrup M
J Control Release
. 2012 Jun;
162(1):159-66.
PMID: 22709589
Biodegradable poly(lactide-co-glycolide) (PLGA) microspheres (MS) deliver antigens and toll like receptor (TLR) ligands to antigen presenting cells (APC) in vitro and in vivo. PLGA-MS-microencapsulated model antigens are efficiently presented on...